
Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80 mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics
Keywords: Degarelix; GnRH receptor antagonist; GnRH receptor blocker; Leuprolide; Prostate cancer; PSA